Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Orthopedics, E-Da Hospital, I-Shou University, Kaohsiung City, Taiwan.
J Cardiovasc Pharmacol. 2022 Nov 1;80(5):732-738. doi: 10.1097/FJC.0000000000001334.
Doxorubicin is a widely used anticancer drug in clinical practice, and its myocardial toxicity is the main concern in oncotherapy. Statins are commonly used as hypolipidemic drugs. Recent studies have also focused on the effects of statins on autophagy. Autophagy is a process in which cells consume their own cytoplasm or organelles after stimulation and finally degrade the phagosome in the lysosome. Transcription factor EB (TFEB) is the main factor regulating lysosomal gene transcription and function. We found that atorvastatin (ATO) increased TFEB protein levels and the ratio of lysosomal-associated membrane protein 2/LC3B in the myocardial tissue of mice with doxorubicin-induced cardiomyopathy (DIC). Therefore, we speculated that ATO may improve cardiac function in mice with DIC by increasing the expression of TFEB to enhance lysosomal function and autophagy. This study explored the role of TFEB in DIC and the possible mechanism of ATO in improving DIC and used statins to prevent and treat DIC; various dilated cardiomyopathy and heart failure diseases provide more experimental evidence. All relevant data are within the article and its supporting information files.
多柔比星是临床实践中广泛使用的抗癌药物，其心肌毒性是肿瘤治疗中的主要关注点。他汀类药物通常被用作降脂药物。最近的研究还集中在他汀类药物对自噬的影响上。自噬是一种细胞在受到刺激后消耗自身细胞质或细胞器，最终在溶酶体中降解吞噬体的过程。转录因子 EB（TFEB）是调节溶酶体基因转录和功能的主要因素。我们发现阿托伐他汀（ATO）增加了多柔比星诱导的心肌病（DIC）小鼠心肌组织中 TFEB 蛋白水平和溶酶体相关膜蛋白 2/LC3B 的比值。因此，我们推测 ATO 可能通过增加 TFEB 的表达来增强溶酶体功能和自噬，从而改善 DIC 小鼠的心脏功能。这项研究探讨了 TFEB 在 DIC 中的作用以及 ATO 改善 DIC 的可能机制，并使用他汀类药物预防和治疗 DIC；为各种扩张型心肌病和心力衰竭疾病提供了更多的实验证据。所有相关数据均在文章及其支持信息文件中。
